The EU Horizon 2020 project imSAVAR  starts 1th December 2019. The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy safety and efficacy. IZBI will contribute by designing cellular and molecular biomarkers for early detection of adverse effects. imSAVAR brings together more than 20 partners from […]